APA (7th ed.) Citation

CK, K., SU, A., TP, R., Y, V., S, J., SC, S., . . . RJ, A. (2024). A Novel Combinatorial Regimen Using Sorafenib and Uttroside B, A US FDA-designated 'Orphan Drug', for the Treatment of Hepatocellular Carcinoma. Anti-cancer agents in medicinal chemistry, 24(19), 1431. https://doi.org/10.2174/0118715206316190240527160242

Chicago Style (17th ed.) Citation

CK, Keerthana, et al. "A Novel Combinatorial Regimen Using Sorafenib and Uttroside B, A US FDA-designated 'Orphan Drug', for the Treatment of Hepatocellular Carcinoma." Anti-cancer Agents in Medicinal Chemistry 24, no. 19 (2024): 1431. https://doi.org/10.2174/0118715206316190240527160242.

MLA (9th ed.) Citation

CK, Keerthana, et al. "A Novel Combinatorial Regimen Using Sorafenib and Uttroside B, A US FDA-designated 'Orphan Drug', for the Treatment of Hepatocellular Carcinoma." Anti-cancer Agents in Medicinal Chemistry, vol. 24, no. 19, 2024, p. 1431, https://doi.org/10.2174/0118715206316190240527160242.